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Abstract
background: Interferon alpha2 is widely used in hepatitis and high-risk melanoma. Interferon-
induced pulmonary arterial hypertension as a side effect is rare.
Case presentation: We describe a melanoma patient who developed severe pulmonary arterial
hypertension 30 months after initiation of adjuvant interferon alpha2b therapy. Discontinuation of
interferon did not improve pulmonary arterial hypertension. This patient could be treated
successfully with phosphodiesterase-5 inhibitor therapy.
Conclusion: This is only the 5th case of interferon-induced pulmonary arterial hypertension and
the first documented case where pulmonary arterial hypertension was not reversible after
termination of interferon alpha2 therapy. If interferon alpha2 treated patients develop respiratory
symptoms, pulmonary arterial hypertension should be considered in the differential diagnosis. For
these patients phosphodiesterase-5 inhibitors, e.g. sildenafil or vardenafil, could be an effective
therapeutic approach.
Background
The interferons (IFN) are a group of glycoproteins pro-
duced by a wide range of cells in response to viruses,
mitogens, double-stranded RNA and other substances.
They perform immunoregulatory, as well as antiviral and
antineoplastic functions, with the latter being the result of
inhibition of cell proliferation, enhanced MHC expres-
sion and tumor-associated antigen expression. The alpha
interferon's (IFN α2a and IFN α2b) act as immunomodu-
lators by enhancing natural killer cells, macrophages and
T-lymphocyte function, as well as having antiangiogenic
properties. Various forms of IFNs have been evaluated as
therapy in a variety of malignant and non-malignant dis-
eases. The major oncologic indications for IFNs include
malignant melanoma, renal cell carcinoma (RCC), AIDS-
related or HHV-8 associated Kaposi's sarcoma, cutaneous
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T-cell lymphoma, hairy cell leukemia, and chronic myel-
ogenous leukemia (CML), whereas the non-oncologic
indications include viral infections (including hepatitis C
and HPV-associated lesions such as condylomata acumi-
nata), multiple sclerosis, keloids, keratoacanthoma, Beh-
cet's disease or hemangioma [1]. IFN α2 is approved in
the US and Europe for adjuvant therapy of melanoma and
is considered the standard therapy for high-risk
melanoma [2]. Among the side effects are flu-like symp-
toms such as fever, chills and anorexia, myalgia, as well as
neuropathies and neuropsychiatric side effects, bone mar-
row depression, liver and renal failure, heart failure, car-
diac arrhythmias, peripheral hypo- and hypertension and
vascular side effects like Raynaud's phenomena, digital
ulceration and gangrene [2,3]. Pulmonary arterial hyper-
tension (PAH) and interstitial pneumonitis are described
as rare side effects [3-8]. We describe a female patient with
high risk melanoma who developed severe PAH 30
months after initiation of adjuvant IFN therapy and who
could be treated successfully with PDE-5 inhibitor
therapy.
Case Presentation
A 40-year-old woman received excision of a superficial
spreading melanoma from the rima ani with a safety mar-
gin of 3 cm (Clark-Level IV, tumor thickness 1,82 mm).
Lymphatic drainage was detected to both inguinal basins
and both excised sentinel lymph nodes were unaffected.
None of the staging examinations including computer
tomography (CT) of the brain, chest, abdomen and pelvis,
as well as lymph node sonography revealed any signs of
tumor manifestation. The medical history of the patient
was otherwise unremarkable and she was not on any med-
ication. There was no family history of hypertension,
heart disease or pulmonary disease. Because of the high-
risk nature of the melanoma, the patient started long-term
adjuvant therapy with IFN α2b (5 × 10 million U. s.c. per
week for 4 weeks followed by 3 × 10 million U. s.c. per
week).
After 30 months of IFN α2b treatment the patient
reported increasing dyspnea on exertion and afebrile non-
productive coughing accompanied by sudden malaise
and edema of the lower legs. Electrocardiography showed
sinus tachycardia (120 /min) and right axis deviation. A
chest x-ray showed signs of right ventricular dilatation and
pleural effusion on the right side; no pneumonic infil-
trates were seen. Abdominal sonography revealed a signif-
icant amount of ascites. The patient was diagnosed with
decompensated right heart failure and was therefore hos-
pitalized. Initial investigations with transthoracic echocar-
diography showed right ventricular hypertrophy and
dilatation (Figure 1), PAH with a calculated systolic pul-
monary artery pressure (PAPsyst) of 80 mmHg and tricus-
pid insufficiency grade II-III with morphologically normal
valves (Figure 2), a reduced right ventricular ejection frac-
tion of 40%, a hypokinetic right ventricle and pericardial
effusion without signs of tamponade. Laboratory work-up
showed slightly increased levels of d-dimers and liver
enzymes, while inflammatory markers were within the
normal range. There were no signs of vasculitis, hyperco-
agulability or rheumatologic disorders. A high-resolution
CT of the chest revealed no signs of pulmonary embolism,
alveolar or interstitial lung diseases, but signs of PAH with
a widened central pulmonary artery (40 mm), right ven-
tricular dilatation (> 80 mm), regurgitation of contrast
medium into liver veins, a circular pericardial effusion
and a 300–400 ml pleural effusion of the right side.
Diagnostic right heart catheter revealed a PAPmean of 56
mmHg (PAPsyst 87 mmHg), a pulmonary vascular resist-
ance (PVR) of 1.128 dyn × sec × cm-5, an impaired cardiac
index and a 3 fold increased total peripheral resistance.
Testing of pulmonary vasoreactivity showed a reduction
of PAPmean from 56 mmHg to 26 mmHg with the PDE-5-
inhibitor sildenafil (Table 1).
Therefore, treatment with 3 × 25 mg sildenafil per day was
initiated. No side effects occurred. After one month, tri-
cuspid insufficiency improved to grade I-II. After six
months right ventricular hypertrophy and dilatation were
reduced. Because of the 2 documented cases of patients
with PAH due to therapy with IFNα2 where PAH was
reversible half a year after termination of IFNα2 [3,4] we
attempted to terminate sildenafil under control of hemo-
dynamic monitoring. PAPmean increased promptly to 57
mmHg. In this context we could verify the same effective-
ness for therapy with vardenafil in comparison to sildena-
fil. Reduction of PVR was higher in vardenafil vs.
sildenafil (Table 1); therefore the therapy was switched
from sildenafil to vardenafil 10 mg twice daily. 24 months
after onset of PAH the patient felt fine and resumed work-
ing. Vardenafil is still necessary to lower her PAP as dem-
onstrated with transthoracic echocardiography: after
pausing vardenafil for two days the PAPsyst  increased
about 40 mmHg, but decreased again 120 minutes after
administration of vardenafil. The heart diameter is stead-
ily decreasing (right ventricular outflow tract from 39 to
27 mm and right atrium from 60–65 to 36–44 mm).
Regarding the melanoma she remains relapse-free.
Conclusion
IFN α2 is an accepted adjuvant treatment for patients with
high risk melanoma [2]. Among the vascular complica-
tions reported for IFN are retinopathy [9], cutaneous vas-
culitis [10], gangrene requiring amputation and biopsy
proven pulmonary vasculitis [3]. PAH includes various
forms with different etiologies, but similar clinical presen-
tation and functional derangement. Although PAH
remains a rare disease, in recent times PAH related toCardiovascular Ultrasound 2005, 3:26 http://www.cardiovascularultrasound.com/content/3/1/26
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other diseases has been better recognized. These forms are
related to systemic connective tissue diseases, throm-
boembolic disease, congenital heart disease, portal hyper-
tension, HIV infection, or are secondary to the use of
drugs. They all result in an indistinguishable histological
picture [11]. In addition to common hypertrophy of the
tunica media, other proliferative lesions such as intimal
thickening or plexiform lesions can be found. Moreover,
in situ thrombosis and rarely isolated pulmonary arteritis
can be observed in lungs of patients displaying PAH. Dif-
ferent pathomechanisms explaining these morphological
changes of pulmonary vasculature have been discussed in
the past, including endothelial and thrombocytic dys-
function, vasoconstriction, coagulation abnormalities, or
cancer-like growth [12]. It is therefore of interest that
IFNα can cause thrombotic microangiopathy which
might contribute to the development of PAH [13].
Various cellular pathway abnormalities have been
described that may play important roles in the develop-
ment and progression of PAH [14,15]. These include
altered synthesis of nitric oxide (NO), prostacyclin and
endothelin, impaired potassium channel and growth fac-
tor receptor function, altered serotonin transporter regula-
tion, increased oxidant stress, and enhanced matrix
production [14-17]. However, the relative importance of
each of these processes remains unclear. It has been
reported, that in sheep IFNα is able to increase the PVR
and the PAP by activation of the thromboxane-cascade
with elevated levels of thromboxane-B2 in plasma and
Right ventricular hypertrophy and dilatation at initial investigation with transthoracic echocardiography Figure 1
Right ventricular hypertrophy and dilatation at initial investigation with transthoracic echocardiography.Cardiovascular Ultrasound 2005, 3:26 http://www.cardiovascularultrasound.com/content/3/1/26
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lung lymph [18]. Studies on the importance of inflamma-
tory mediators, such as chemokines, in the lungs of PAH
patients have led to a possible inflammatory component
in the development of PAH [19]. This might be of
relevance in IFN induced PAH since IFNα is known to
induce expression of various chemokines [20].
All PAH result in similar histological remodelling of pul-
monary arteries with thickening of the intima, prolifera-
tion of the media and plexogenic lesions. Today the
pathophysiology of these lesions is much better under-
stood and has resulted in new therapies involving sub-
stances such as prostacyclins, endothelin receptor
antagonists or PDE-5 inhibitors, aimed not only at dilat-
ing arteries but also at preventing their remodelling.
Sildenafil and vardenafil inhibit PDE-5, an enzyme that is
abundantly expressed in pulmonary vasculature [21].
PDE-5 is the major guanosine 3',5'-cyclic monophosphate
(cGMP) degrading phosphodiesterase. PDE-5 gene
expression and activity are increased in PAH [22]. Sildena-
fil binds to the catalytic site of PDE-5 approximately a
thousand times more avidly than the natural substrate,
cGMP [23]. cGMP is the second messenger of prostacyclin
and NO and due to stabilization of this second messenger,
therapy with PDE-5 inhibitors leads to prolongation of
Tricuspid insufficiency grade II–III with a morphological normal valve at initial investigation with transthoracic echocardiography Figure 2
Tricuspid insufficiency grade II–III with a morphological normal valve at initial investigation with transthoracic 
echocardiography.Cardiovascular Ultrasound 2005, 3:26 http://www.cardiovascularultrasound.com/content/3/1/26
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prostanoid- and NO-related vascular effects [24]. In
patients with PAH, short-term application of sildenafil
during right heart catheterization showed the potential to
reduce PVR in a dose-dependent manner. Interestingly,
the vasodilator effects were significantly stronger than
with inhaled NO [25]. Advantages of a potential therapy
with PDE-5-inhibitors for PAH are p.o. administration, an
excellent safety profile and relatively low treatment costs
[26]. A number of studies have shown the effectiveness of
a therapy with PDE-5 inhibitors for PAH [25-32]. Because
of the low incidence of this condition the number of
patients studied is small. One study could show a long-
lasting benefit with sildenafil with respect to hemody-
namic and clinical parameters over 3, 6 and 12 months
[26]. A recently published placebo-controlled and rand-
omized phase III study revealed a significant reduction of
PAP, improvement of 6-minute-walk test and reduction of
hospitalization due to PAH [32].
Data are rare for the use of different PDE-5 inhibitors
other than sildenafil in PAH. The in vitro biochemical
potentials of sildenafil and vardenafil are comparable,
whereas vardenafil has a binding affinity to PDE-5 more
than ten times higher than sildenafil [33]. One could
speculate that therapy with vardenafil in PAH could be
more effective than with sildenafil due to its higher bind-
ing affinity to PDE-5. In a small study with different PDE-
5 inhibitors in PAH, the reduction of PAP with sildenafil
and vardenafil was comparable, while sildenafil showed
surprisingly more selectivity for the pulmonary circula-
tion and a better arterial oxygenation compared to varde-
nafil [34]. In the case presented our patient responded
favorably to both sildenafil and vardenafil.
This is only the 5th case of IFN-induced PAH [3-5,7]. The
previous patients received IFN for CML (three patients) or
RCC (one patient). Our patient developed PAH after 2.5
years of adjuvant IFNα treatment, in the other cases the
range was from several months up to 22 months after ini-
tiation of IFN therapy. In two cases PAH was reversible
within 6 months after termination of IFNα therapy. In
one case, the patient died 2 years after withdrawal from
IFN therapy. An autopsy was not performed, but the
authors suggested a systemic microangiopathy caused by
IFNα as underlying reason [5]. To the best of our knowl-
edge this is the first documented case where PAH was not
reversible after termination of IFNα therapy and there was
a need for continuous vasodilator therapy. Treatment
with PDE-5-inhibitors had, in this case, a long-lasting
beneficial effect. If IFNα treated patients develop respira-
tory symptoms, PAH should be considered in the differen-
tial diagnosis. For these patients PDE-5 inhibitors, e.g.
sildenafil or vardenafil, could be an effective therapeutic
approach.
Abbreviations
cGMP = guanosine 3'5'-cyclic monophosphate
CML = chronic myelogenous leukemia
CT = computer tomopgraphy
IFN = Interferon
PAH = pulmonary arterial hypertension
PAP = pulmonary arterial pressure
Table 1: Testing of pulmonary vasoreactivity at initial investigation and after six months of PDE-5 inhibitor therapy with right heart 
catheter
HR RR mmHg 
syst/diast 
(mean)
PAP 
mmHg syst/
diast 
(mean)
RA mmHg PCWP 
mmHg
CI l/min/m2 SV ml/m2 TPR dyn × 
sec × cm-5
PVR dyn × 
sec × cm-5
baseline 103 140/89 
(104)
87/37 (56) 28 8 1,9 33 3.178 1.128
baseline 
sildenafil
96 106/58 (76) 74/14 (26) 13 3 2,2 41 1.290 760
six months 
sildenafil
96 105/71 (88) 64/27 (43) 8 4 2,6 46 1.453 708
six months 
vardenafil
102 114/69 (83) 63/25 (40) 6 6 2,6 44 1.403 604
baseline = initial investigation; baseline sildenafil = 90 minutes after first dose of 25 mg sildenafil p.o.; six months sildenafil = after 6 months of 
therapy with sildenafil; six months vardenafil = 120 minutes after first dose of 10 mg vardenafil p.o. HR = heart rate; RR = blood pressure; PAP = 
pulmonary arterial pressure; RA = right atrial pressure; PCWP = pulmonary capillary wedge pressure; CI = cardiac index; SV = stroke volume; TPR 
= total peripheral resistance; PVR = pulmonary vascular resistance.Cardiovascular Ultrasound 2005, 3:26 http://www.cardiovascularultrasound.com/content/3/1/26
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PDE-5 = phosphodiesterase-5
PVR = pulmonary vasculature resistance
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